drugset / Trial / NCT06795412
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.
Timeline
- Start
- 2025-04-15
- Primary completion
- 2027-12-06
- Completion
- 2027-12-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PYX-201 | Other / unclassified | — | Intravenous |
| Background | Pembrolizumab | Monoclonal antibody | — | Intravenous |